PREPARATION AND CHARACTERIZATION OF ORAL NANOSUSPENSION LOADED WITH CURCUMIN
Objective: The principle objective of the present research work was to improve the bioavailability of curcumin (CUR) by decreasing its particle size. Nanosuspension (NS) of CUR was prepared using poloxamer-188 (P188) as a surfactant. The prepared NSs were characterized for particle size, polydispersity index (PDI), zeta potential, drug loading, saturation solubility, and drug release kinetic studies.
Methods: Components required for NS preparation, such as solvent, anti-solvent and surfactant were screened. Precipitation high-speed homogenization (HSH) method was used for the preparation of NS using selected components. Evaluation of NS for particle size, PDI, drug loading, saturation solubility and in vitro drug release was done. Pharmacokinetic studies of the NS in sprague dawley (SD) rats were performed.
Results: The particle size, PDI and zeta potential of the optimized formulation was 596.5Â±5 nm, 0.233Â±0.010 and-23Â±2 mV respectively. The pH of all the formulations was in the range of 5-6 which is acceptable when related to drug stability. The optimized formulation showed an increase in saturation solubility in water and phosphate buffer pH 6.8 when compared to plain CUR suspension (S). Results of pharmacokinetic studies indicated that Cmax and AUC0-6 were increased 8 and 10 times respectively from plain CUR S to CUR NS.
Conclusion: CUR NS was prepared using P188 as the stabilizer. Amongst various stabilizers screened P188 rendered a stable NS with the particle size in nano range. Pharmacokinetic studies revealed the better performance of CUR NS as compared to plain CUR S.
2. Nidhi A, Chandana M, Chakraborthy GS. Natural herbs as anticancer drugs. Int J PharmTech Res 2012;4:1142-53.
3. Rajashree H, Vilasrao K. Preparation and characterization of inclusion complexes of carvedilol with methyl-Î²-cyclodextrin. J Incl Phenom Macrocycl Chem 2009;63:219-24.
4. Rajashree H, Harshal G, Vilasrao K. Solid-state characterization of the inclusion complex of valsartan with methyl Î²-cyclodextrin. J Incl Phenom Macrocycl Chem 2009; 65:377-83.
5. Rajashree H, Harshal G, Vilasrao K. Solid lipid nanoparticles and nanostructured lipid carriers: a review. Curr Drug Ther 2011;6:240-50.
6. Samar AA, Maha AH, Ali SA, Kadria AE. Nanosuspension: an emerging trend for bioavailability enhancement of etodolac. Int J Polym Sci 2015;1-16. http://dx.doi.org/10.1155/2015/ 938594.
7. Vandana BP, Abhijit AD, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol 2004;56:827-40.
8. Preetha A, Ajaikumar BK, Robert AN, Bharat BA. Bioavailability of curcumin: problems and promises. Mol Pharm 2007;4:807-18.
9. Muller RH. Colloidal carriers for controlled drug delivery and targeting. Modification, characterization, and in vivo distribution. J Controlled Release 1992;18:279-80.
10. Yan G. Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as a stabilizer. Drug Dev Ind Pharm 2010;36:1225â€“34.
11. Rupali LS, Nilesh K. Formulation and evaluation of a nanosuspension delivery system for simvastatin. Int J Pharm Sci Nanotech 2014;7:2459-76.
12. Jeevana JB, Sravani R. Development of curcumin nanocrystals and evaluation of GIT absorption efficiency in copmparison with curcumin and turmeric powder. World J Pharm Pharm Sci 2016;5:1990-2003.
13. Hintz RJ, Johnson KC. The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm 1989;51:9-17.
14. Sachin KS, Jasmine K, Palak B, Sarvi YR, Parth S, Deepak G, et al. Formulation of curcumin nanosuspension using box-behnken design and study of the impact of drying techniques on its powder characteristics. Asian J Pharm Clin Res 2017;10:43-51.
15. Smita SA, Malsane ST, Saudagar RB. Nanosuspension: an overview. Int J Curr Pharm Res 2017;9:19-23.